New Zealand's Pharmac will fund Novo Nordisk's long-acting insulin therapy RYZODEG (insulin degludec and insulin aspart) from 1 May under an agreement that could benefit around 13,000 people in year one. …
Latest Video
New Stories
-
Challenging headlines are the natural consequence of disrupting a very stale debate
April 15, 2025 - - Latest News -
ViiV Healthcare announces the recipients of 2024 Positive Action Community Grants
April 15, 2025 - - Latest News -
US FDA announces plan to phase-out animal testing in drug development
April 15, 2025 - - Latest News -
Medicines Australia appoints new senior policy executive
April 15, 2025 - - Latest News -
This could be a path forward, a move to delay, or both, and we've seen it before
April 14, 2025 - - Latest News -
API launches new B2B e-commerce platform to support its more than 4,000 customers
April 14, 2025 - - Latest News -
Sorry minister, but there's no world in which you kept this election commitment to newborns
April 14, 2025 - - Latest News